[go: up one dir, main page]

JO3052B1 - أدوية جالينية عضوية ناتجة عن السماح بالإنطلاق المحوًر لمادة التركيب النشطة - Google Patents

أدوية جالينية عضوية ناتجة عن السماح بالإنطلاق المحوًر لمادة التركيب النشطة

Info

Publication number
JO3052B1
JO3052B1 JOP/2008/0408A JOP20080408A JO3052B1 JO 3052 B1 JO3052 B1 JO 3052B1 JO P20080408 A JOP20080408 A JO P20080408A JO 3052 B1 JO3052 B1 JO 3052B1
Authority
JO
Jordan
Prior art keywords
active ingredient
modified release
galenical form
form allowing
dividable
Prior art date
Application number
JOP/2008/0408A
Other languages
English (en)
Inventor
Genty Patrick
Wuthrich Patrick
Fonknechten Gilles
- Manuel Pean Jean
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3052(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of JO3052B1 publication Critical patent/JO3052B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

شكل غلاييني عضوي منقسم للاطلاق المعًدل للمكون الفعال، حيث ان الانقسام الثانوي للشكل الغلاييني بنسبة الشكل المذكور يتم الحصول عليهم عن طريق انقسام ثانوي يملك صورة متطابقة الذوبان الأدوية
JOP/2008/0408A 2008-03-21 2008-09-11 أدوية جالينية عضوية ناتجة عن السماح بالإنطلاق المحوًر لمادة التركيب النشطة JO3052B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
JO3052B1 true JO3052B1 (ar) 2017-03-15

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2008/0408A JO3052B1 (ar) 2008-03-21 2008-09-11 أدوية جالينية عضوية ناتجة عن السماح بالإنطلاق المحوًر لمادة التركيب النشطة

Country Status (36)

Country Link
US (3) US20090238870A1 (ar)
EP (2) EP3025706A1 (ar)
JP (2) JP5231906B2 (ar)
KR (3) KR20090101048A (ar)
CN (1) CN101347414B (ar)
AP (1) AP2729A (ar)
AR (1) AR067993A1 (ar)
AU (1) AU2008207680B8 (ar)
CA (1) CA2629670C (ar)
CL (1) CL2008002486A1 (ar)
CO (1) CO6020017A1 (ar)
CR (2) CR10317A (ar)
CU (1) CU23970B1 (ar)
EA (1) EA200801862A1 (ar)
EC (1) ECSP088727A (ar)
FR (1) FR2928836B1 (ar)
GT (1) GT200800163A (ar)
HK (1) HK1127280A1 (ar)
HN (1) HN2008001466A (ar)
IL (1) IL193611A0 (ar)
JO (1) JO3052B1 (ar)
MA (1) MA31218B1 (ar)
ME (1) ME01031B (ar)
MX (1) MX2008011579A (ar)
MY (1) MY150660A (ar)
NI (1) NI200800256A (ar)
NZ (1) NZ570715A (ar)
PE (1) PE20090991A1 (ar)
SA (1) SA08290555B1 (ar)
SG (1) SG155819A1 (ar)
SV (1) SV2008003023A (ar)
TW (1) TWI396561B (ar)
UA (1) UA86731C2 (ar)
UY (1) UY31307A1 (ar)
WO (1) WO2009125087A1 (ar)
ZA (1) ZA200807354B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
WO2021185804A1 (en) 2020-03-16 2021-09-23 Grünenthal GmbH Scored tablet

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
EP2332522A3 (en) * 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ATE387905T1 (de) * 1998-04-03 2008-03-15 Kyowa Hakko Kogyo Kk Teilbare tablette und durchdrückpackung
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
EA200401009A1 (ru) * 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
BRPI0609636B8 (pt) * 2005-04-08 2021-05-25 Abbott Lab formulação oral de liberação modificada que compreende um agente ativo e um revestimento entérico
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
CN102008392B (zh) * 2005-08-18 2013-07-31 帝人制药株式会社 具有准确的用量分割功能的制剂
RU2008113439A (ru) * 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
NZ574954A (en) * 2006-08-10 2011-11-25 Takeda Pharmaceutical Pharmaceutical composition comprising 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl} -1H-benzimidazole-7-carboxylic acid
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
SG155819A1 (en) 2009-10-29
SA08290555B1 (ar) 2011-07-20
JP2009227651A (ja) 2009-10-08
ECSP088727A (es) 2008-10-31
KR20110112266A (ko) 2011-10-12
CA2629670A1 (fr) 2008-10-01
ME01031B (me) 2012-10-20
KR101693189B1 (ko) 2017-01-05
KR20150035829A (ko) 2015-04-07
HK1127280A1 (en) 2009-09-25
MX2008011579A (es) 2009-09-21
HN2008001466A (es) 2011-04-25
NZ570715A (en) 2010-10-29
US20090238870A1 (en) 2009-09-24
AU2008207680B2 (en) 2010-04-22
EA200801862A1 (ru) 2009-10-30
PE20090991A1 (es) 2009-07-18
TW200940109A (en) 2009-10-01
IL193611A0 (en) 2009-08-03
AP2729A (en) 2013-08-31
MY150660A (en) 2014-02-14
JP2010209103A (ja) 2010-09-24
JP5231906B2 (ja) 2013-07-10
CR10317A (es) 2008-11-26
FR2928836A1 (fr) 2009-09-25
MA31218B1 (ar) 2010-03-01
GT200800163A (es) 2010-05-21
EP2103302A1 (fr) 2009-09-23
US20130295176A1 (en) 2013-11-07
CU20080179A7 (es) 2011-04-26
FR2928836B1 (fr) 2011-08-26
NI200800256A (es) 2010-02-11
EP3025706A1 (fr) 2016-06-01
BRPI0803631A2 (pt) 2011-03-29
UA86731C2 (ru) 2009-05-12
AU2008207680B8 (en) 2010-05-13
SV2008003023A (es) 2010-07-29
CN101347414B (zh) 2011-11-23
UY31307A1 (es) 2008-10-31
WO2009125087A1 (fr) 2009-10-15
CU23970B1 (es) 2013-12-27
CL2008002486A1 (es) 2008-12-26
CN101347414A (zh) 2009-01-21
CR20140334A (es) 2014-08-20
AP2008004614A0 (en) 2008-10-31
CA2629670C (fr) 2012-04-17
US20140221449A1 (en) 2014-08-07
KR20090101048A (ko) 2009-09-24
TWI396561B (zh) 2013-05-21
CO6020017A1 (es) 2009-03-31
ZA200807354B (en) 2008-11-26
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
JO3052B1 (ar) أدوية جالينية عضوية ناتجة عن السماح بالإنطلاق المحوًر لمادة التركيب النشطة
PL2808325T3 (pl) Podstawione azole, przeciwwirusowy składnik czynny, kompozycja farmaceutyczna, sposób ich wytwarzania i stosowania
IL210561A (en) Production items that release an active ingredient, a method of making and using them
CA141113S (en) Dispenser for pharmaceutical powder formulations
WO2014009833A3 (en) Complement pathway modulators and uses thereof
MX350447B (es) Composicion farmaceutica de disolucion rapida.
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
WO2012085657A3 (en) Tamper resistant solid oral dosage forms
BR112012001353A2 (pt) anel vaginal, e, métodos para fabricar um anel vaginal e para dispensar um ou mais ingredientes farmaceuticamente ativos
MX359288B (es) Forma iv del clorhidrato de ivabradina.
PH12012501258A1 (en) Processes for the manufacture of a pharmaceutically active agent
MY191875A (en) Solid dosage form
NZ598427A (en) Stabilized amorphous forms of imatinib mesylate with cyclodextrin complex
TW200942530A (en) Pyridine compounds
USD653700S1 (en) Typeface
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
WO2011005052A8 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
WO2010115125A3 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
ME02057B (me) Farmaceutska kompozicija sa antimikrobnim djelovanjem i za ubrzano zacjeljivanje, za spoljašnju administraciju, procesi za njeno dobijanje
WO2012127495A3 (en) Pharmaceutical composition and process for preparation thereof
WO2011062936A3 (en) Self-assembled toroidal-spiral particles and manufacture and uses thereof
WO2011059207A3 (en) Arylpiperazine-containing purine derivatives and uses thereof
UA48323U (ru) Способ лечения вич/спид-ассоциированного туберкулеза
MY197131A (en) Fast dissolving solid dosage form